Rocket Pharmaceuticals Q3 EPS $(0.75) Beats $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals reported Q3 losses of $(0.75) per share, beating the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.87) per share from the same period last year.
November 06, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rocket Pharmaceuticals' Q3 losses were less than expected, which could be seen as a positive sign by investors.
Rocket Pharmaceuticals reported lower than expected losses for Q3, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100